<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）在目前覆盖该股票的十六家评级公司中获得了 “适度买入” 的平均评级，Marketbeat.com 报道。一位分析师对该股票给予了卖出建议，三位分析师给予了持有建议，十二位分析师对该公司发出了买入建议。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价格为 38.8571 美元。</p>
<p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家低调的医疗保健公司</li>
</ul>
<p>TVTX 最近成为多份分析师报告的主题。TD Cowen 在 10 月 31 日（星期五）的一份研究报告中重新发布了对 Travere Therapeutics 股票的 “买入” 评级。花旗集团将 Travere Therapeutics 的目标价格从 34.00 美元上调至 48.00 美元，并在 10 月 31 日（星期五）的一份研究报告中给予该股票 “买入” 评级。华尔街禅在 12 月 13 日（星期六）的一份研究报告中将 Travere Therapeutics 的评级从 “买入” 上调至 “强力买入”。HC Wainwright 在 11 月 28 日（星期五）的一份报告中重申了 “买入” 评级，并对 Travere Therapeutics 股票设定了 47.00 美元的目标价。最后，Weiss Ratings 在 1 月 21 日（星期三）的一份研究报告中重申了对 Travere Therapeutics 股票的 “卖出（e+）” 评级。</p>
<p><strong>阅读我们对 Travere Therapeutics 的最新分析</strong></p>
<h2>Travere Therapeutics 的内部交易</h2>
<ul>
<li>在鼓舞人心的数据发布后，Travere Therapeutics 仍在上升</li>
</ul>
<p>在其他新闻中，首席执行官 Eric M. Dube 于 1 月 27 日（星期二）出售了 51,865 股公司的股票。股票以平均价格 30.10 美元出售，总价值为 1,561,136.50 美元。交易完成后，首席执行官持有公司 419,173 股股票，价值 12,617,107.30 美元。这代表着他们持有的股票减少了 11.01%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。此外，内部人士 William E. Rote 于 12 月 24 日（星期三）出售了 60,000 股股票。该股票以平均价格 40.10 美元出售，总交易额为 2,406,000.00 美元。出售后，该内部人士直接持有公司 101,443 股股票，价值 4,067,864.30 美元。这代表着他们的持股减少了 37.16%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 179,858 股公司股票，价值 6,408,552 美元。当前 4.19% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近修改了对 TVTX 的持股。先锋集团在第三季度将其在 Travere Therapeutics 的持股增加了 10.3%。先锋集团现在拥有 6,613,368 股公司股票，价值 158,059,000 美元，在上个季度又购买了 619,085 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Travere Therapeutics 的持股增加了 27.4%。Adage Capital Partners GP L.L.C.现在拥有 2,784,000 股公司股票，价值 41,203,000 美元，在上个季度又收购了 599,102 股。Emerald Advisers LLC 在第三季度将其在 Travere Therapeutics 的持股增加了 2.6%。Emerald Advisers LLC 现在拥有 2,146,767 股公司股票，价值 51,308,000 美元，在上个季度又收购了 55,407 股。Geode Capital Management LLC 在第二季度将其在 Travere Therapeutics 的持股增加了 1.4%。Geode Capital Management LLC 现在拥有 2,003,701 股公司股票，价值 29,658,000 美元，在上个季度又购买了 27,040 股。最后，Stephens Investment Management Group LLC 在第三季度收购了价值约 38,232,000 美元的 Travere Therapeutics 新股份。</p>
<h2>Travere Therapeutics 股票表现</h2>
<p>TVTX 股票在周二开盘价为 33.10 美元。该股票的市值为 29.6 亿美元，市盈率为-31.23，市盈增长比率为 1.02，贝塔值为 0.85。该股票的 50 日移动平均线为 34.17 美元，200 日移动平均线为 27.64 美元。该公司的债务与股本比率为 4.23，流动比率为 2.75，速动比率为 2.71。Travere Therapeutics 的一年最低价为 12.91 美元，一年最高价为 42.13 美元。</p>
<h2>关于 Travere Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Travere Therapeutics, Inc.（纳斯达克：TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小型患者群体的疾病，解决治疗选择有限的疾病中的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
<p>该公司的主要产品是 sparsentan，一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Travere Therapeutics</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>黄金正在变得稀缺。</li>
<li>美国更新</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
<p>在考虑投资 Travere Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Travere Therapeutics 并不在名单上。</p>
<p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVTX

<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX）获得分析师的共识评级为 “适度买入”，其中包括十二个买入推荐、三个持有和一个卖出。平均 12 个月目标价为 38.86 美元。最近的分析师报告显示，花旗集团将目标价上调至 48.00 美元，并给予华尔街 Zen 强烈买入评级。内部交易显示首席执行官 Eric M. Dube 及其他人进行了大量股票出售。机构投资者也增加了他们的持股。目前该股票价格为 33.10 美元，市值为 29.6 亿美元，年内最高价为 42.13 美元</p>

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has received an average rating of &#34;Moderate Buy&#34; from the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $38.8571.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）在目前覆盖该股票的十六家评级公司中获得了 “适度买入” 的平均评级，Marketbeat.com 报道。一位分析师对该股票给予了卖出建议，三位分析师给予了持有建议，十二位分析师对该公司发出了买入建议。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价格为 38.8571 美元。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家低调的医疗保健公司</li>
</ul>
</div><p>TVTX has been the topic of a number of recent analyst reports. TD Cowen reissued a &#34;buy&#34; rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Citigroup raised their price objective on Travere Therapeutics from $34.00 to $48.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, October 31st. Wall Street Zen raised Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, December 13th. HC Wainwright restated a &#34;buy&#34; rating and issued a $47.00 price target on shares of Travere Therapeutics in a report on Friday, November 28th. Finally, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st.</p>
<div class="lb-trans"><p>TVTX 最近成为多份分析师报告的主题。TD Cowen 在 10 月 31 日（星期五）的一份研究报告中重新发布了对 Travere Therapeutics 股票的 “买入” 评级。花旗集团将 Travere Therapeutics 的目标价格从 34.00 美元上调至 48.00 美元，并在 10 月 31 日（星期五）的一份研究报告中给予该股票 “买入” 评级。华尔街禅在 12 月 13 日（星期六）的一份研究报告中将 Travere Therapeutics 的评级从 “买入” 上调至 “强力买入”。HC Wainwright 在 11 月 28 日（星期五）的一份报告中重申了 “买入” 评级，并对 Travere Therapeutics 股票设定了 47.00 美元的目标价。最后，Weiss Ratings 在 1 月 21 日（星期三）的一份研究报告中重申了对 Travere Therapeutics 股票的 “卖出（e+）” 评级。</p>
</div><p><strong>Read Our Latest Analysis on Travere Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Travere Therapeutics 的最新分析</strong></p>
</div><h2>Insider Transactions at Travere Therapeutics</h2>
<div class="lb-trans"><h2>Travere Therapeutics 的内部交易</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>在鼓舞人心的数据发布后，Travere Therapeutics 仍在上升</li>
</ul>
</div><p>In other news, CEO Eric M. Dube sold 51,865 shares of the company's stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $30.10, for a total value of $1,561,136.50. Following the completion of the transaction, the chief executive officer owned 419,173 shares in the company, valued at $12,617,107.30. This represents a 11.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider William E. Rote sold 60,000 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $40.10, for a total transaction of $2,406,000.00. Following the sale, the insider directly owned 101,443 shares of the company's stock, valued at $4,067,864.30. This represents a 37.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 179,858 shares of company stock valued at $6,408,552. 4.19% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Eric M. Dube 于 1 月 27 日（星期二）出售了 51,865 股公司的股票。股票以平均价格 30.10 美元出售，总价值为 1,561,136.50 美元。交易完成后，首席执行官持有公司 419,173 股股票，价值 12,617,107.30 美元。这代表着他们持有的股票减少了 11.01%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。此外，内部人士 William E. Rote 于 12 月 24 日（星期三）出售了 60,000 股股票。该股票以平均价格 40.10 美元出售，总交易额为 2,406,000.00 美元。出售后，该内部人士直接持有公司 101,443 股股票，价值 4,067,864.30 美元。这代表着他们的持股减少了 37.16%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 179,858 股公司股票，价值 6,408,552 美元。当前 4.19% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of TVTX. Vanguard Group Inc. grew its holdings in shares of Travere Therapeutics by 10.3% during the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock worth $158,059,000 after buying an additional 619,085 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Travere Therapeutics by 27.4% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock worth $41,203,000 after acquiring an additional 599,102 shares during the last quarter. Emerald Advisers LLC grew its stake in shares of Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock worth $51,308,000 after acquiring an additional 55,407 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Travere Therapeutics by 1.4% in the second quarter. Geode Capital Management LLC now owns 2,003,701 shares of the company's stock valued at $29,658,000 after purchasing an additional 27,040 shares during the last quarter. Finally, Stephens Investment Management Group LLC acquired a new stake in shares of Travere Therapeutics in the third quarter valued at approximately $38,232,000.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近修改了对 TVTX 的持股。先锋集团在第三季度将其在 Travere Therapeutics 的持股增加了 10.3%。先锋集团现在拥有 6,613,368 股公司股票，价值 158,059,000 美元，在上个季度又购买了 619,085 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Travere Therapeutics 的持股增加了 27.4%。Adage Capital Partners GP L.L.C.现在拥有 2,784,000 股公司股票，价值 41,203,000 美元，在上个季度又收购了 599,102 股。Emerald Advisers LLC 在第三季度将其在 Travere Therapeutics 的持股增加了 2.6%。Emerald Advisers LLC 现在拥有 2,146,767 股公司股票，价值 51,308,000 美元，在上个季度又收购了 55,407 股。Geode Capital Management LLC 在第二季度将其在 Travere Therapeutics 的持股增加了 1.4%。Geode Capital Management LLC 现在拥有 2,003,701 股公司股票，价值 29,658,000 美元，在上个季度又购买了 27,040 股。最后，Stephens Investment Management Group LLC 在第三季度收购了价值约 38,232,000 美元的 Travere Therapeutics 新股份。</p>
</div><h2>Travere Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票表现</h2>
</div><p>Shares of TVTX stock opened at $33.10 on Tuesday. The stock has a market cap of $2.96 billion, a PE ratio of -31.23, a price-to-earnings-growth ratio of 1.02 and a beta of 0.85. The stock has a 50-day moving average of $34.17 and a 200-day moving average of $27.64. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. Travere Therapeutics has a one year low of $12.91 and a one year high of $42.13.</p>
<div class="lb-trans"><p>TVTX 股票在周二开盘价为 33.10 美元。该股票的市值为 29.6 亿美元，市盈率为-31.23，市盈增长比率为 1.02，贝塔值为 0.85。该股票的 50 日移动平均线为 34.17 美元，200 日移动平均线为 27.64 美元。该公司的债务与股本比率为 4.23，流动比率为 2.75，速动比率为 2.71。Travere Therapeutics 的一年最低价为 12.91 美元，一年最高价为 42.13 美元。</p>
</div><h2>About Travere Therapeutics</h2>
<div class="lb-trans"><h2>关于 Travere Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克：TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小型患者群体的疾病，解决治疗选择有限的疾病中的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>该公司的主要产品是 sparsentan，一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>The day the gold market broke</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>Gold’s getting scarce.</li>
<li>End of America Update</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Travere Therapeutics</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>黄金正在变得稀缺。</li>
<li>美国更新</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Travere Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Travere Therapeutics 并不在名单上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Travere Therapeutics, Inc. (NASDAQ:TVTX) 获得分析师一致推荐为 “适度买入”